Vallon Pharmaceuticals, Inc. (VLON): Price and Financial Metrics


Vallon Pharmaceuticals, Inc. (VLON): $0.56

0.01 (+1.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VLON to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VLON Stock Price Chart Interactive Chart >

Price chart for VLON

VLON Price/Volume Stats

Current price $0.56 52-week high $3.45
Prev. close $0.56 52-week low $0.34
Day low $0.52 Volume 77,100
Day high $0.60 Avg. volume 2,470,812
50-day MA $1.35 Dividend yield N/A
200-day MA $1.84 Market Cap 3.83M

Vallon Pharmaceuticals, Inc. (VLON) Company Bio


Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.


VLON Latest News Stream


Event/Time News Detail
Loading, please wait...

VLON Latest Social Stream


Loading social stream, please wait...

View Full VLON Social Stream

Latest VLON News From Around the Web

Below are the latest news stories about Vallon Pharmaceuticals Inc that investors may wish to consider to help them evaluate VLON as an investment opportunity.

Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update

- T opline data for p ivotal abuse study of the C ompany’s lead investigational program ADAIR expected this quarter

GlobeNewswire | February 14, 2022

Vallon Pharmaceuticals reports FY results

Vallon Pharmaceuticals press release (VLON): FY 2021 Net loss was $9.3M.Cash, cash equivalents and marketable securities of ~$7.5M

Seeking Alpha | February 14, 2022

Even with Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) stock down 13% this week, insiders who bought recently netted around US$20k

Vallon Pharmaceuticals, Inc. ( NASDAQ:VLON ) insiders who acquired shares over the previous 12 months, can probably...

Yahoo | January 25, 2022

Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference

– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that David Baker, President and Chief Executive Officer will present at the Virtual Investor 2022

Yahoo | January 20, 2022

Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference

- Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall®, are the most commonly abused preparation of prescription stimulants - Company’s abuse-deterrent stimulant formulations have the potential to address misuse and abuse of stimulant medication by non-oral routes, such as snorting - Pivotal abuse study of the Company’s lead investigational program ADAIR completed enrollment and dosing with topline data expected this quarter PHILADELPHIA, PA, J

Yahoo | January 18, 2022

Read More 'VLON' Stories Here

VLON Price Returns

1-mo -54.84%
3-mo -77.27%
6-mo -69.29%
1-year -58.00%
3-year N/A
5-year N/A
YTD -71.91%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4736 seconds.